MDSpire - Summary
From the Journals
Commentary & Perspectives

Influencer Drug Promotion Raises Concerns

Study highlights regulatory gaps and persuasive risks in social media marketing

Share

A scoping review published in JAMA Network Open, led by Sascha Gell, MA, highlights the growing public health concerns related to influencer promotion of prescription drugs. The review examined 12 articles, revealing misinformation, regulatory gaps, and the often misleading personal narratives of influencers that can obscure promotional intent. Notably, while some influencers offer invaluable peer support, their inaccurate health claims can lead to significant dangers. Additionally, the need for clearer regulatory guidance and increased accountability from both pharmaceutical companies and social media platforms emerges as vital for consumer safety.

Original Source(s)

Influencer Drug Promotion Raises Concerns

  • by Kerri Miller

  • March 23, 2026

Related Content

Metabolic Acidosis Care Limited in Chronic Kidney Disease

Low testing rates may contribute to underdiagnosis and undertreatment in Japan

The Past, Present and Future of Non-Target Screening

Thomas Letzel reflects on the evolution of non-target screening and why interdisciplinary insights are key to its future

  • March 23, 2026

  • 9 min
From Crisis to Compliance: Navigating Europe’s Toughest Medical Device Rules

Compliance is no longer a background function — it is central to maintaining access